Rusan Pharma achieves GMP approvals from TGA (Australia) and ANVISA (Brazil) for its manufacturing facility in Kandla SEZ
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The new facility marks a significant milestone for Fredun Pharmaceuticals as it expands its footprint in the rapidly growing pet care industry in India
Subscribe To Our Newsletter & Stay Updated